Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
September 24, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
August 21, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results
August 07, 2019 16:05 ET
|
Constellation Pharmaceuticals , Inc.
Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2...
Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
June 13, 2019 14:57 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
June 12, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals,...
Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
June 03, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CPI-0610 showed signals of clinical activity, both as a monotherapy and in combination with ruxolitinib, in refractory myelofibrosis (MF) patientsPatients treated with CPI-0610 exhibited improvement...
Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference
May 31, 2019 11:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
May 23, 2019 10:28 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
May 20, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation...
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
May 16, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
Data published in two abstracts suggest that CPI-0610 may have potential disease-modifying effects in treating myelofibrosis All ten evaluable patients experienced spleen volume reductions...